{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:17:39Z","timestamp":1789186659221,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.eclinm.2022.101790","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T12:39:06Z","timestamp":1672058346000},"page":"101790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled Phase 4 trial"],"prefix":"10.1016","volume":"56","author":[{"given":"Antigone","family":"Kotsaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tziolos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theano","family":"Kontopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis M.","family":"Koutelidakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Symbardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaughan","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"O'Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Sambatakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Toutouzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Akinosoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvina","family":"Lada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"MacGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2022.101790_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","article-title":"Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different Gram-positive bacterial infections","volume":"41","author":"Poliseno","year":"2021","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.eclinm.2022.101790_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.diagmicrobio.2008.08.009","article-title":"Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America emerging infections network survey","volume":"62","author":"Beekmann","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.eclinm.2022.101790_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2022.101790_bib6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2022.101790_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2022.101790_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/jac\/27.4.558","article-title":"Synergistic interaction of antibiotics with nasal penetration to methicillin-sensitive and methicillin-resistant Staphylococcus aureus","volume":"27","author":"Chow","year":"1991","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2022.101790_bib9","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jac\/dkab112","article-title":"The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in\u00a0vitro pharmacokinetic model of infection","volume":"76","author":"Noel","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2022.101790_bib10","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.00206-07","article-title":"Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus","volume":"51","author":"Cenizal","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eclinm.2022.101790_bib11","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/AAC.00262-07","article-title":"Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"51","author":"Ruhe","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eclinm.2022.101790_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jgar.2016.07.010","article-title":"Methicillin-resistant Staphylococcus aureus infections: a review of the currently available treatment options","volume":"7","author":"Purrello","year":"2016","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.eclinm.2022.101790_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/jac\/dku352","article-title":"Randomized non-inferiority trial to compare trimethoprim\/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection","volume":"70","author":"Harbarth","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2022.101790_bib14","doi-asserted-by":"crossref","first-page":"A231","DOI":"10.1016\/j.jval.2015.03.1342","article-title":"Clinical comparison of full course intravenous or abbreviated oral antibiotics in hospitalized patients with methicillin-resistant S.\u00a0aureus (MRSA) skin and soft tissue infections","volume":"18","author":"Jacobs","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.eclinm.2022.101790_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2014.04.007","article-title":"Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria","volume":"44","author":"Eckmann","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eclinm.2022.101790_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/1469-0691.12632","article-title":"Pan-European early switch\/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections","volume":"20","author":"Nathwani","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eclinm.2022.101790_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A\u00a0randomized clinical trial of single-dose versus\u00a0weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2022.101790_bib18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2022.101790_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022005193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022005193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:19:09Z","timestamp":1762899549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022005193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":17,"alternative-id":["S2589537022005193"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101790","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled Phase 4 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101790"}}